This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C75 | Special Copayment Reduction: V193 | Copayment 5% (for 5 years from the date of cancer patient registration) C75.0 parathyroid gland, C75.1 pituitary gland, C75.2 craniopharyngeal duct, C75.3 pineal gland, C75.4 carotid body, C75.5 aortic body and other paraganglia, C75.8 pluriglandular involvement, C75.9 unspecified |
| B. Synonyms | Parathyroid carcinoma, pituitary malignancy, craniopharyngioma (malignant), pineal malignancy, carotid body tumor, multiple endocrine gland neoplasm, Parathyroid carcinoma, Pituitary carcinoma, Craniopharyngioma (malignant), Pineal carcinoma, Carotid body tumor, MEN1·MEN2 related neoplasm |
| C. Adult onset | Very high — parathyroid carcinoma in the 30s–60s; pituitary malignancy in adults; MEN1-related tumors in adults; craniopharyngioma in children and adults (bimodal peak); pineal malignancy in children to adolescents |
Malignant neoplasms of other endocrine glands under C75 encompass a very diverse range. Parathyroid carcinoma was first reported by de Quervain in 1904 and is an extremely rare malignancy accounting for 0.5–5% of all primary hyperparathyroidism. Until the first half of the 20th century, clinical differentiation from parathyroid adenoma was very difficult, and in 1973 Schantz and Castleman proposed histological diagnostic criteria. The discovery of the HRPT2 (CDC73) gene in parathyroid carcinoma (2002) greatly advanced the molecular understanding of this disease.
Pituitary carcinoma accounts for only 0.1–0.5% of pituitary tumors, and most cases arise by transformation of an atypical adenoma to malignancy. By definition, extracranial metastasis (craniospinal or systemic metastasis) must be present for classification as malignant. Since 2004, temozolomide has been reported to be effective in aggressive pituitary adenomas and pituitary carcinoma. Craniopharyngioma derives from Rathke's pouch and is histologically benign but strongly locally invasive, and some cases of malignant transformation have been reported. This classification also includes malignant carotid body tumors and aortic paragangliomas. MEN1·MEN2 were first described clinically in 1954 (MEN1) and 1959 (MEN2), and molecular genetics later confirmed that mutations of the MEN1 and RET genes, respectively, are the causes.
The causes of the various malignancies in the C75 classification differ by tumor type. Risk factors for parathyroid carcinoma: history of head and neck irradiation, MEN1 syndrome (MEN1 gene mutation), germline mutations of the HRPT2/CDC73 gene (malignant parathyroid tumors, jaw-ossifying fibroma — hyperparathyroidism-jaw tumour syndrome). Most are sporadic. Risk factors for pituitary malignancy: the MEN1 gene (increased risk of pituitary adenoma), cranial irradiation (inducing secondary malignancy). Growth hormone-secreting adenomas can arise in Carney complex (PRKAR1A mutation). Response to temozolomide treatment is associated with MGMT promoter methylation.
Craniopharyngioma: there are two subtypes, characterized by BRAF V600E mutation in the papillary type (squamopapillary) and CTNNB1 (β-catenin) mutation in the adamantinomatous type. Carotid body tumors and paragangliomas: germline variants of SDH (SDHB/C/D) genes, VHL variants and NF1 variants are the main genetic causes, and familial occurrence is common. In familial paraganglioma-pheochromocytoma syndrome, SDH-related genetic predisposition is the most common. Pineal malignancies are mostly sporadic, with no clear genetic risk factors.
The genetics of C75 endocrine gland malignancies is classified by tumor type. Parathyroid carcinoma: somatic and germline mutations of the HRPT2 (CDC73) gene (1q25-q32) are found in 70–100% of parathyroid carcinomas. The CDC73 protein (parafibromin) is a component of a histone methyltransferase complex, and its loss of function promotes cell proliferation. CCND1 (cyclin D1) overexpression is also frequently observed. MEN1 syndrome: mutation of the MEN1 gene (11q13) → loss of function of the menin protein → dysregulation of histone methylation → development of multiple endocrine gland tumors. Parathyroid, pituitary and pancreatic endocrine tumors arise together.
Pituitary malignancy: CCND1 amplification, CDKN2A loss and TP53 mutations are found in aggressive pituitary tumors. MGMT promoter methylation is a predictive marker of temozolomide response. PD-L1 expression is used to select candidates for immune checkpoint inhibitor therapy. Craniopharyngioma: papillary type — BRAF V600E (over 90%), potentially responsive to dabrafenib+trametinib; adamantinomatous type — CTNNB1 activating mutations, constitutive activation of the Wnt pathway. Paraganglioma: mutations of the SDH (B/C/D), VHL, RET, NF1, MAX and TMEM127 genes are identified in 80–90% of hereditary tumors. SDHB mutation is most strongly associated with malignant metastatic paraganglioma.
The malignancies included in C75 are, overall, extremely rare. Parathyroid carcinoma occurs in about 200–300 cases per year in the United States, accounting for about 0.5–5% of all primary hyperparathyroidism. It occurs mainly in the 30s–60s with no sex difference. Pituitary malignancy accounts for 0.1–0.5% of all pituitary tumors and is a very rare tumor with only a few dozen cases reported per year. High density of round fibroblasts and metastasis are the diagnostic criteria. Craniopharyngioma accounts for about 6–9% of pediatric intracranial tumors, with an annual incidence of about 0.13 per 100,000 population, and shows a bimodal peak in children (5–14 years) and in the 50s–60s.
Carotid body tumors and paragangliomas are rare at 1–2 per 1 million population, with markedly higher incidence in SDH mutation carriers. Familial paragangliomas account for about 30–40% of the total. The proportion of malignant (metastatic) paragangliomas is about 10–23%. Pineal malignancies (pineal germinoma, pineoblastoma, etc.) account for 0.5–1% of all brain tumors and are common mainly in males in their 10s–30s. MEN1 is rare at about 2–3 per 100,000 population, and MEN2 at about 2 per 100,000. In Korea, MEN-related endocrine gland malignancies are treated intensively at a small number of specialized centers.
In the pathogenesis of parathyroid carcinoma, loss of parafibromin function due to CDC73 (HRPT2) gene mutation is central. Parafibromin is a component of PAF1c (polymerase associated factor 1 complex), participates in regulating gene expression through histone H3K4 methylation, and suppresses cell proliferation. Loss of parafibromin → release of cell cycle inhibition → CCND1 (cyclin D1) overexpression → promotion of the G1/S transition → unlimited proliferation of parathyroid cells. In pituitary malignancy, loss of MEN1 (menin) causes disruption of its complex with the histone methyltransferases MLL1/2, upregulating vascular endothelial growth factor (VEGF) and several growth factors.
In adamantinomatous craniopharyngioma, CTNNB1 activating mutation → prevention of β-catenin degradation → nuclear accumulation → activation of Wnt target genes (cyclin D1, c-Myc) → cell proliferation. In the papillary type, BRAF V600E → constitutive activation of the MAPK-ERK pathway → promotion of cell proliferation and survival. In malignant paraganglioma, loss of SDH complex function → disruption of the electron transport chain → succinate accumulation → inhibition of TET2 enzymes → DNA hypermethylation → epigenomic alteration → angiogenesis and acquisition of a metastatic phenotype. In MEN1, menin is responsible for suppressing Wnt/MAPK signaling, regulating the cell cycle and promoting apoptosis, and loss of these functions causes hyperproliferation of various endocrine cells.
The symptoms of C75 endocrine gland malignancies vary greatly by type. Parathyroid carcinoma: symptoms of severe hypercalcemia due to excessive parathyroid hormone (PTH) secretion are central. Kidney stones (renal colic), bone pain (osteoporosis, osteitis fibrosa cystica), polydipsia and polyuria, nausea, vomiting and constipation, muscle weakness, fatigue, declining renal function (renal failure), cognitive decline ("bones, stones, groans, psychic moans"). Severe hypercalcemia (>14 mg/dL) causes altered consciousness and cardiac arrhythmias and is life-threatening. Pituitary malignancy: symptoms of hormone hypersecretion (varying by adenoma type) — Cushing disease (ACTH secretion), acromegaly (GH secretion), hyperprolactinemia (infertility, amenorrhea, galactorrhea), hyperthyroidism (TSH secretion). Systemic symptoms when metastasis occurs.
Craniopharyngioma: visual loss due to pituitary-hypothalamic compression (optic chiasm compression), headache, hypopituitarism (growth delay, precocious puberty/delayed sexual development), diabetes insipidus. Carotid body tumor: neck mass, pulsatile neck swelling, dysphagia, hoarseness. Malignant paraganglioma: with excessive catecholamine secretion, headache, palpitations, sweating and hypertensive crises. In nonfunctioning tumors, an abdominal mass and abdominal pain are the main symptoms. MEN1: gastric acid hypersecretion (ZE syndrome), hypoglycemia (insulinoma), kidney stones (hypercalcemia) and headache (pituitary tumor) occur in combination.
In parathyroid carcinoma, marked elevation of serum calcium (≥13–14 mg/dL) and very marked elevation of serum PTH (3–10 times normal) are the key biochemical findings. On neck palpation, a neck mass attached to the thyroid may be felt (rarely palpable in parathyroid adenoma). As signs of bone disease, osteoporosis of the distal radius and spine and pathological fractures are seen on imaging. Renal ultrasound shows multiple kidney stones and nephrocalcinosis. In pituitary malignancy, in addition to hormonal abnormalities, visual field defects according to tumor size (bitemporal hemianopia), signs of raised intracranial pressure and signs of brain metastasis may appear.
In craniopharyngioma, visual field testing (perimetry) shows bitemporal hemianopia or a unilateral visual field defect. On MRI, a suprasellar cystic+solid tumor with calcification is characteristic. In children, growth failure and delayed sexual development are the main clinical findings. In malignant paraganglioma, a pulsatile mass may be palpated on abdominal palpation, and CT shows an enhancing mass around the aorta. Carotid body tumor is characterized by a neck mass that does not move laterally on the Fontaine test.
Screening strategies for C75 malignancies focus on hereditary syndromes. MEN1 patients and families: after identifying mutation carriers by MEN1 gene testing, the parathyroid glands (annual serum calcium and PTH), pituitary gland (brain MRI every 3–5 years) and pancreatic endocrine tumors (abdominal CT/MRI or endoscopic ultrasound) are monitored regularly. MEN2 (RET mutation): mutation carriers are identified by RET gene testing, and in MEN2A, evaluation of parathyroid function (calcium, PTH) and regular testing for pheochromocytoma (metanephrines) are needed. After pheochromocytoma is excluded, the timing of prophylactic resection for medullary thyroid cancer is decided.
Families with VHL syndrome: in VHL gene mutation carriers, hemangioblastomas and paragangliomas are monitored with MRI of the skull base, neck, chest and abdomen. SDH mutation carriers: head and neck and abdominal MRI, regular measurement of urine/plasma metanephrines (every 1–2 years). Groups at risk for parathyroid carcinoma (HRPT2 germline mutation, families with hyperparathyroidism-jaw tumor syndrome): annual serum calcium and PTH measurement and neck ultrasound. When hypercalcemia is found in the general population, evaluation for primary hyperparathyroidism should be performed to differentiate malignancy. There are no population screening programs for malignant craniopharyngioma, pituitary carcinoma or pineal malignancies.
Diagnosis of parathyroid carcinoma: measurement of serum calcium (>14 mg/dL), PTH (elevated several-fold above normal), 24-hour urine calcium and serum alkaline phosphatase (ALP). Lesion localization by imaging—99mTc-sestamibi scan, neck ultrasound, CT, MRI, 4D-CT. Preoperative biopsy is contraindicated because of the risk of seeding malignant cells. Confirmation is based on postoperative histology—fibrous bands, vascular invasion, capsular invasion, a thick fibrous capsule and a high mitotic count. On immunohistochemistry, loss of parafibromin expression is strong supporting evidence of malignancy.
Pituitary malignancy: extracranial metastasis is confirmed with brain MRI, cerebrospinal fluid cytology (leptomeningeal metastasis) and whole-body CT/PET. Hormones such as ACTH, GH and prolactin are measured. Ki-67>3% is used to predict aggressive behavior. Craniopharyngioma: brain MRI (cystic+solid suprasellar tumor), visual field testing, endocrine function tests. Confirmation of histologic type (adamantinomatous vs papillary) and BRAF V600E/CTNNB1 mutation by biopsy or after surgery. Malignant paraganglioma/carotid body tumor: CT/MRI/PET (Ga-68 DOTATATE or F-18 FDOPA), plasma and urine metanephrines, SDH gene testing.
Parathyroid carcinoma: complete surgical resection is the only curative treatment. En bloc resection of the ipsilateral thyroid lobe, the abnormal parathyroid gland and adjacent tissue is standard. For recurrence or metastasis, re-resection (repeat surgery) is effective. Cinacalcet (a calcimimetic) is used to control hypercalcemia, and bisphosphonates and denosumab are used for bone lesions. The efficacy of radiotherapy and chemotherapy is very limited. Pituitary malignancy: postoperative radiotherapy or stereotactic radiosurgery (SRS). Temozolomide is effective in MGMT methylation-positive aggressive pituitary adenomas/carcinomas. Application of PD-1 inhibitors (pembrolizumab) is being studied.
Craniopharyngioma: maximal safe resection followed by radiotherapy is standard, and conservative resection + radiotherapy may be more favorable than complete resection for preserving endocrine function. In the papillary type, responses to BRAF V600E inhibitors (dabrafenib+trametinib) have been reported, and the treatment paradigm is changing. Targeted therapy against the Wnt pathway (adamantinomatous type) is being studied. Malignant paraganglioma: surgical resection, radiotherapy, MIBG therapy (I-131), Ga-68/Lu-177 DOTATATE PRRT. In progressive metastatic SDH-mutant paraganglioma, DTIC (dacarbazine), cyclophosphamide+vincristine+dacarbazine (CVD) or sunitinib is used.
The 5-year overall survival of parathyroid carcinoma is about 50–70%, improving to about 85% with complete resection. However, the recurrence rate is high (50–60%), and repeat surgery is often needed. When distant metastasis (lung, liver, bone) occurs, the prognosis worsens sharply. Most deaths are due to severe hypercalcemia rather than tumor invasion. Pituitary malignancy has a poor prognosis after diagnosis, with most patients dying within a few years; median survival is about 2–4 years. Some improvement is possible with temozolomide.
Craniopharyngioma is histologically benign but recurs locally often, and long-term complications such as hypothalamic-pituitary dysfunction, visual impairment and obesity greatly reduce quality of life. The 10-year survival rate is about 60–90%, but the burden of complications is high. The 5-year survival of malignant paraganglioma is about 50–70%, but tumors with SDH mutations, especially SDHB mutations, have high metastasis rates and a poor prognosis. The prognosis of MEN1-related malignancies varies with the organs involved and tumor size, and is good with early detection. Malignant carotid body tumors have a relatively favorable prognosis after complete resection, but a poor prognosis when metastasis occurs.
The most important strategy in preventing C75 malignancies is early detection and surveillance of hereditary syndromes. MEN1 gene mutation carriers: parathyroid, pituitary and pancreatic tumors are detected and treated early through regular biochemical and imaging surveillance. In particular, in MEN1 patients with hyperparathyroidism, prophylactic parathyroidectomy helps prevent hypercalcemia. MEN2 carriers: determining the timing of prophylactic total thyroidectomy according to the type and risk level of the RET mutation is key to preventing medullary thyroid cancer, and regular surveillance for pheochromocytoma is also important.
HRPT2/CDC73 mutation carriers (families with hyperparathyroidism-jaw tumor syndrome): early detection of malignant parathyroid tumors is attempted with regular serum calcium and PTH measurement, neck ultrasound and jaw imaging. SDH mutation carriers: regular MRI and biochemical tests are used for early detection of malignant paraganglioma and to decide the timing of treatment. In the general population, if symptoms of hyperparathyroidism (kidney stones, bone pain, symptoms of hypercalcemia) occur, prompt endocrinology evaluation should be obtained. Radiation exposure should be minimized, and especially in patients who have received head and neck radiotherapy, the risk of secondary endocrine tumors should be recognized and regular checkups performed.